Evidence map›Paper›PMID 39833902›Full record

ReviewPediatric rheumatology online journal2025

Reducing the risk of visual disability for children with juvenile idiopathic arthritis uveitis through disease surveillance: past and future challenges.

Ameenat Lola Solebo, Ivan Foeldvari

Abstract readReview
In one paragraph

Review in Pediatric rheumatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. The gut-joint axis in juvenile idiopathic arthritis.Arthritis research & therapy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ameenat Lola SoleboUveitis Department, Great Ormond Street Hospital NHS Foundation Trust, London, UK. a.solebo@ucl.ac.uk.ORCID http://orcid.org/0000-0002-8933-5864
Ivan FoeldvariHamburger Zentrum für Kinder- und Jugendrheumatologie, am Schön Klinik Hamburg Eilbek, Hamburg, Germany.

Funding

National Institute for Health and Care Research CS-2018-18-ST2-005
6 · The paper itself

Abstract

Childhood blindness significantly impacts development, education, employment, and mental health, creating burden for families and society. Between 8% and 30% of children with Juvenile Idiopathic Arthritis (JIA) develop a potentially blinding chronic inflammatory eye disease, uveitis (JIAU). Alongside the use of disease-modifying agents and anti-TNF immunomodulators, JIAU surveillance has helped to reduce the risk of JIAU related blindness.Inconsistent guidance on JIAU surveillance has previously been a hindrance to care delivery and access for professional and families. The Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) has brought some much-needed standardisation to JIA surveillance, developing a consensus-based screening proposal which simplifies the protocol, supporting implementation amongst non-specialists, and ensuring that children at risk receive the timely eye examination necessary to avoid life-changing visual disability. In this commentary on the MIWGUC surveillance proposal, we also address the implementation of such surveillance. A global shortage of ophthalmologists threatens the sustainability of these surveillance programs. Innovative approaches could be imaging-based detection. The accessibility of Optical Coherence Tomography (OCT) imaging may make OCT a feasible future option for community-based surveillance, reducing the burden on ophthalmologists, and on patients and their families.

Indexed as

Arthritis, JuvenileBlindnessUveitisVision DisordersChildHumansTomography, Optical Coherence

Identifiers

PMID39833902
PMCPMC11744860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.